Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 10
Submit an article Journal homepage
169
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation

Svetlana A. SmirnikhinaLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-1558-3048View further author information
ORCID Icon,
Ekaterina Yu. ChelyshevaScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0001-6423-1789View further author information
ORCID Icon,
Alexander V. LavrovLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; ;Department of Molecular and Cellular Genetics, The Russian National Research Medical University Named after N.I. Pirogov, Moscow, Russian FederationORCID Iconhttp://orcid.org/0000-0003-4962-6947View further author information
ORCID Icon,
Konstantin S. Kochergin-NikitskyLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0002-0096-4542View further author information
ORCID Icon,
Ivan V. MozgovoyDepartment of Molecular and Cellular Genetics, The Russian National Research Medical University Named after N.I. Pirogov, Moscow, Russian FederationView further author information
,
Elmira P. AdilgereevaLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0002-6440-0500View further author information
ORCID Icon,
Oleg A. ShukhovScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0001-5393-0816View further author information
ORCID Icon,
Anna N. PetrovaScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; View further author information
,
Anastasia V. BykovaScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; View further author information
,
Adhamjon O. AbdullaevScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0003-2530-808XView further author information
ORCID Icon,
Anna G. TurkinaScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0001-9947-2371View further author information
ORCID Icon &
Sergey I. KutsevLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; ;Department of Molecular and Cellular Genetics, The Russian National Research Medical University Named after N.I. Pirogov, Moscow, Russian FederationORCID Iconhttp://orcid.org/0000-0002-3133-8018View further author information
ORCID Icon show all
Pages 2512-2515 | Received 17 Aug 2017, Accepted 21 Jan 2018, Published online: 09 Feb 2018

References

  • Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29:1123–1132.
  • Sauszele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–1647.
  • Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17–23.
  • Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–1531.
  • Bhalla S, Tremblay D, Mascarenhas J. Discontinuing tyrosine kinase inhibitor therapy in chronic myelogenousleukemia: current understanding and future directions. Clin Lymphoma Myeloma Leuk. 2016;16:488–494.
  • Kimura S. Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia. Stem Cell Investig. 2016;3:36
  • Campiotti L, Suter MB, Guasti L, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer. 2017;77:48–56.
  • Smirnikhina SA, Lavrov AV, Chelysheva EY, et al. Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients. Leuk Lymphoma. 2016;57:1669–1676.
  • Camicia R, Bachmann SB, Winkler HC, et al. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma. J Cell Sci. 2013;126:1969–1980.
  • Bachmann SB, Frommel SC, Camicia R, et al. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Mol Cancer. 2014;13:125.
  • Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.
  • Matoulkova E, Michalova E, Vojtesek B, et al. The role of the 3' untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol. 2012;9:563–576.
  • Mignone F, Gissi C, Liuni S, et al. Untranslated regions of mRNAs. Genome Biol. 2002;3:REVIEWS0004
  • Wang B, Yang H, Shen L, et al. Rs56288038 (C/G) in 3'UTR of IRF-1 Regulated by MiR-502-5p Promotes Gastric Cancer Development. Cell Physiol Biochem. 2016;40:391–399.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.